AIM ImmunoTech Statistics

Total Valuation

AIM ImmunoTech has a market cap or net worth of GBP 6.98 million. The enterprise value is 3.97 million.

Market Cap	6.98M
Enterprise Value	3.97M

Important Dates

The next estimated earnings date is Wednesday, April 2, 2025.

Earnings Date	Apr 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+7.96%
Shares Change (QoQ)	+9.16%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	54.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	24.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.22
EV / Sales	26.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.26

Financial Position

The company has a current ratio of 0.75, with a Debt / Equity ratio of 1.17.

Current Ratio	0.75
Quick Ratio	0.71
Debt / Equity	1.17
Debt / EBITDA	n/a
Debt / FCF	-0.16
Interest Coverage	-61.64

Financial Efficiency

Return on equity (ROE) is -187.58% and return on invested capital (ROIC) is -117.65%.

Return on Equity (ROE)	-187.58%
Return on Assets (ROA)	-84.20%
Return on Invested Capital (ROIC)	-117.65%
Return on Capital Employed (ROCE)	-800.49%
Revenue Per Employee	5,250
Profits Per Employee	-661,238
Employee Count	28
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.50% in the last 52 weeks. The beta is -0.30, so AIM ImmunoTech's price volatility has been lower than the market average.

Beta (5Y)	-0.30
52-Week Price Change	-69.50%
50-Day Moving Average	0.19
200-Day Moving Average	0.39
Relative Strength Index (RSI)	38.01
Average Volume (20 Days)	9,702

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.99

Income Statement

In the last 12 months, AIM ImmunoTech had revenue of GBP 141,759 and -17.85 million in losses. Loss per share was -0.34.

Revenue	141,759
Gross Profit	114,899
Operating Income	-20.83M
Pretax Income	-17.85M
Net Income	-17.85M
EBITDA	-20.65M
EBIT	-20.83M
Loss Per Share	-0.34

Full Income Statement

Balance Sheet

The company has 5.37 million in cash and 2.54 million in debt, giving a net cash position of 2.84 million.

Cash & Cash Equivalents	5.37M
Total Debt	2.54M
Net Cash	2.84M
Net Cash Per Share	n/a
Equity (Book Value)	2.17M
Book Value Per Share	0.04
Working Capital	-1.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.44 million and capital expenditures -5,969, giving a free cash flow of -15.44 million.

Operating Cash Flow	-15.44M
Capital Expenditures	-5,969
Free Cash Flow	-15.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	81.05%
Operating Margin	-14,695.26%
Pretax Margin	-12,594.21%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

AIM ImmunoTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.96%
Shareholder Yield	-7.96%
Earnings Yield	-255.87%
FCF Yield	-221.33%

Stock Splits

The last stock split was on June 11, 2019. It was a reverse split with a ratio of 0.0227272727.

Last Split Date	Jun 11, 2019
Split Type	Reverse
Split Ratio	0.0227272727

Scores

AIM ImmunoTech has an Altman Z-Score of -49.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-49.17
Piotroski F-Score	n/a